Skip to content

Read-only version: For security reasons, the Research Information System (FIS) has been temporarily replaced by this read-only version. All public content and full texts remain available; login, editing, submission and statistics are not available. Questions: fis@uni-bamberg.de

Home › Publications › Biomarkers of inflammation and improvement in depressive symptoms in type 1 and type 2 diabetes : differential associations with depressive symptom clusters

Publication

Biomarkers of inflammation and improvement in depressive symptoms in type 1 and type 2 diabetes : differential associations with depressive symptom clusters

Herder, Christian; Zhu, Anna; Schmitt, Andreas; u. a. (2026): Biomarkers of inflammation and improvement in depressive symptoms in type 1 and type 2 diabetes : differential associations with depressive symptom clusters, in: Bamberg: Otto-Friedrich-Universität, S. 2057–2068.

Details

Faculty/Chair
Faculty/Professorship
Author
Herder, Christian
Zhu, Anna
Schmitt, Andreas
Spagnuolo, Maria C.
Roden, Michael
Publisher Information
Otto-Friedrich-Universität : Bamberg
Year of publication
2026
Source/Other editions
Diabetologia, Berlin ; Heidelberg: Springer, 2025, Jg. 68, Nr. 9, S. 2057–2068, ISSN: 1432-0428
Year of first publication
2025
Language
English
Licence
URN
Abstract

Aims/hypothesis:

People with diabetes and depression show large heterogeneity in their response to depression treatment. This study aimed to identify biomarkers of subclinical inflammation that were associated with improvement of depressive symptoms in people with type 1 diabetes and type 2 diabetes.

Methods:

The prospective analysis combined data from three studies (DIAMOS, ECCE HOMO and DDCT). A total of 332 people with type 1 diabetes and 189 people with type 2 diabetes completed both the baseline and 1 year follow-up examinations. Depressive symptoms were assessed using the Center for Epidemiological Studies depression scale (CES-D). Associations between baseline serum levels of 76 biomarkers of inflammation and 1 year changes in depressive symptoms were estimated using multiple linear regression.

Results:

In people with type 2 diabetes, higher levels of 26 biomarkers were associated with greater reductions in depressive symptoms (β=0.128 to 0.255; p<0.05), whereas in people with type 1 diabetes, higher levels of 13 biomarkers were linked with lower reductions in depressive symptoms (β=−0.189 to −0.094; p<0.05). A significant effect modification was observed for 33 biomarkers (pinteraction<0.05). The positive associations in type 2 diabetes were strongest for improvements in cognitive-affective and anhedonia symptoms, while the inverse associations in type 1 diabetes were strongest for improvements in somatic symptoms.

Conclusions/interpretation:

Higher baseline levels of multiple biomarkers of inflammation were associated with greater depression reduction in type 2 diabetes but lower depression reduction in type 1 diabetes. There were also diabetes type-specific differences in the associations with symptom clusters of depression. This suggests that different inflammation-related pathways may be relevant for the response to depression treatment in people with type 1 diabetes or type 2 diabetes.

GND Keywords
Depression
Diabetes mellitus Typ 1
Diabetes mellitus Typ 2
Keywords
Biomarker; CES-D; Depression; Depressive symptoms; Diabetes; Inflammation; Treatment response; Type 1 diabetes; Type 2 diabetes
DDC Classification
150 Psychology
RVK Classification
CU 3200
Peer Reviewed
yes
International Distribution
yes
Open Access Journal
no
Type
Article
URI
Activation date
2026-02-03

Permalink: https://fis.uni-bamberg.de/handle/uniba/112913 · Data as JSON · Cite: BibTeX · RIS

Data as of: 2026-11-16

Restricted read-only access: login, editing and submission are temporarily disabled.